Treatment with PRT543 significantly reduced the survival of both organoid models in a dose-dependent manner (Fig. 3I), and had potent inhibitory effects on MYC and MYB expression (Fig. 3J), the key drivers associated with ACC pathogenesis [96–98]. This evidence concerns the gene MYB and adrenal cortex carcinoma.